IFNB1 and myeloid sarcoma: Similarly, in another study, serum MDA levels were higher in RRMS patients taking no disease-modifying therapy than in those taking interferon beta [12], all suggesting the protective effects of immunomodulation on lipid peroxidation-related detrimental outcomes in MS.